Cancer Xenografts - Blood Transfection

Cancer Xenograft Models in Hematologic Research

Xenograft models are an essential component of modern cancer research. By implanting human tumor cells into immunodeficient mice, researchers can replicate the progression and biology of cancer in a living system. These in vivo models make it possible to study tumor growth, evaluate the efficacy of experimental treatments, and observe molecular changes in real-time under conditions that closely mirror human disease.

Cancer xenografts offer a bridge between in vitro discovery and clinical application. In the context of blood-related cancers, they allow for precise assessment of how therapeutic agents behave within the immune system, circulatory system, and bone marrow microenvironment. This is especially important for blood cancers, where disease spread is systemic rather than localized, and therapeutic targeting must be highly specific.

Understanding Blood Cancers

Blood cancers, also known as hematologic malignancies, originate in the blood-forming tissues such as bone marrow and lymph nodes. Unlike solid tumors, these cancers typically involve cells that circulate throughout the body, including white blood cells, plasma cells, and lymphocytes.

Leukemia is a type of blood cancer that arises in the bone marrow and leads to the overproduction of abnormal white blood cells. It is classified into acute and chronic forms, and may originate from either myeloid or lymphoid lineages. Examples include acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), and T‑cell or B‑cell leukemias.

Lymphoma is another category of blood cancer, originating in lymphatic tissues. It involves the transformation and uncontrolled growth of lymphocytes. Subtypes include Burkitt’s lymphoma, follicular lymphoma, diffuse large B‑cell lymphoma (DLBCL), and mantle cell lymphoma. These malignancies can develop in lymph nodes, spleen, and other tissues of the immune system.

Multiple myeloma is a cancer of plasma cells, which are responsible for producing antibodies. It begins in the bone marrow and leads to bone degradation, immune dysfunction, and kidney damage. Unlike leukemias and lymphomas, myeloma cells often localize in bone lesions, but can still be modeled effectively using xenograft approaches.

Supporting Translational Research and Drug Development

Blood cancer xenograft models are critical for bridging the gap between laboratory research and clinical trials. They allow for the preclinical testing of monoclonal antibodies, kinase inhibitors, CAR-T cell therapies, and small molecules targeting the genetic and immunologic pathways of hematologic cancers.

Using xenograft models, researchers can explore not only tumor volume reduction but also deeper mechanistic insights into resistance, relapse, tumor microenvironment interaction, and immune modulation. These studies are essential for understanding how a therapy performs beyond a petri dish and under real biological pressure.

Altogen Labs offers full-service in vivo study execution, from experimental design to endpoint tissue analysis. Their xenograft models help clients generate reliable, reproducible data that supports regulatory submissions, publications, and therapeutic advancement.

HL-60 Xenograft Model

Overview of the HL‑60 Xenograft Model

The HL‑60 xenograft model is a well-established preclinical platform for studying acute myeloid leukemia (AML) in vivo. HL‑60 cells are a human promyelocytic leukemia cell line originally derived from a 36-year-old female patient with AML. These cells are widely used in cancer biology because of their ability to undergo myeloid differentiation and their responsiveness to various pro-apoptotic and chemotherapeutic compounds. The model mimics key features of human leukemia and is widely accepted for drug efficacy testing, differentiation therapy studies, and translational oncology research.

Scientific Background: HL‑60 Cell Line

HL‑60 cells are suspension cells capable of differentiating into granulocytes, monocytes, or macrophage-like cells in response to specific chemical stimuli such as DMSO or retinoic acid. They express surface markers associated with early myeloid progenitors, including CD33 and CD13, and produce measurable responses to compounds targeting DNA synthesis, apoptosis pathways, and inflammatory signals. Their consistent behavior in vitro and tumorigenic potential in vivo make them a valuable tool for modeling hematologic malignancies.

Xenograft Study Protocol

Altogen Labs uses NOD/SCID or athymic BALB/C mice, typically aged 10–12 weeks, to establish subcutaneous HL‑60 xenografts. Cells are prepared at >98% viability and injected (1×10⁶ cells in 100–150 μL Matrigel) into the hind flank. Tumors generally become palpable within 7–10 days, and growth is monitored using digital calipers. Once tumors reach a volume of 50–150 mm³, mice are randomized into dosing groups. Compounds are administered via custom-defined routes and schedules, with tumor size and body weight recorded multiple times per week.

Study duration typically ranges from 3–6 weeks, depending on tumor growth kinetics and therapeutic effects. Upon reaching endpoint criteria (e.g., 2,000 mm³ tumor volume or defined timepoint), mice are ethically euthanized and undergo necropsy.

Endpoint Analysis and Data Output

Every study includes a complete reporting package that documents all phases of the experiment, from baseline tumor growth to final endpoint analysis. Standard deliverables include tumor growth curves, body weight tracking, gross pathology findings, and photographic records of tumor and tissue samples. Altogen Labs offers a suite of downstream services that includes histopathology, immunohistochemistry, RNA and protein extraction, gene expression profiling, and Western blot analysis. Optional customization allows researchers to define specific molecular or phenotypic readouts aligned with their project goals. All procedures are performed in GLP-compliant facilities under IACUC oversight to ensure high standards of scientific rigor, data reproducibility, and animal care.

Applications and Use Cases

The HL‑60 xenograft model supports a wide range of applications in leukemia and hematologic malignancy research. It is ideal for evaluating drug efficacy in vivo, investigating mechanisms of drug resistance, and assessing compounds that induce differentiation or apoptosis in leukemia cells. This model is also used in pharmacokinetics and pharmacodynamics studies, toxicity screening, and biomarker discovery. Its reproducible tumor growth and well-documented lineage biology provide a robust platform for testing both small molecule drugs and biologics.

Request an Instant Quote: https://altogenlabs.com/request-quote/hl60-xenograft-model-services/

Learn more: HL-60 Xenograft Model

K562 Xenograft Model

Overview of the K562 Xenograft Model

The K562 xenograft represents a reliable and well-characterized in vivo platform for evaluating chronic myelogenous leukemia (CML) and acute myeloid leukemia (AML) therapies. K562 cells, originally derived from a 53‑year‑old CML patient in blast crisis, are human erythroleukemic and highly undifferentiated, making them a versatile model that can mimic various myeloid phenotypes in vivo. Subcutaneous implantation of these cells into immunodeficient mice creates reproducible solid tumors that are easily measured and suitable for therapeutic efficacy studies .

Scientific Background: K562 Cell Biology

K562 cells share key characteristics with both granulocytes and erythrocytes, carrying the Philadelphia chromosome and expressing the BCR‑ABL1 oncogene. They lack MHC class I expression, rendering them particularly sensitive to natural killer (NK) cell activity, making them a standard target for NK cytotoxicity assays. Their ease of culture, low clumping behavior, and ability to differentiate in response to chemical stimuli such as imatinib or phorbol esters enhance their adaptability across experimental platforms

Xenograft Study Design

Altogen Labs establishes the K562 xenograft model in NOD/SCID or athymic BALB/C mice aged 10 to 12 weeks. Cells are prepared in log-phase at greater than 98 percent viability and mixed with Matrigel prior to subcutaneous injection (1×10^6 cells in 100 µL). Tumor formation is typically detected within 7 to 10 days, with daily volume measurements commenced once tumors reach approximately 75–150 mm³. Animals are randomized into treatment groups and dosed according to the client’s protocol. Tumor volumes are recorded daily with calipers, while body weights are monitored three times per week. Study endpoints are reached when pre-defined criteria—such as a 2,000 mm³ tumor volume or ethical considerations—are met. Animals are then euthanized following GLP and IACUC-compliant protocols.

Endpoint Analysis and Deliverables

Each study includes comprehensive documentation including tumor volume data, animal weight records, and photographic evidence. Necropsies are performed, with tumors weighed, imaged, and processed as required. Altogen offers expanded services such as histopathology, immunohistochemistry, RNA/protein extraction, and molecular analyses. Tissue samples can be snap-frozen, fixed for histology, or processed for nucleic acid isolation based on client specifications.

In Vivo Phenotype and Disease Relevance

K562 xenograft tumors are typically vascularized solid masses with tumor cell morphology reflective of human CML/AML and can demonstrate metastasis to bone marrow and circulation in some cases. In selectin-competent mouse models, K562 infiltration of bone marrow and blood is evident; selectin-deficient models show reduced propagation and prolonged survival, underscoring the model’s utility in studying leukemic cell homing and metastasis.

Request an Instant Quote: https://altogenlabs.com/request-quote/k562-xenograft-model-services/

Learn more: K-562 Xenograft Model

MOLM-13 Xenograft Model

Model Overview

The MOLM‑13 xenograft model employs a human acute myeloid leukemia (AML) cell line derived from a relapsed AML patient. Known for carrying the MLL‑AF9 fusion and FLT3‑ITD mutation, MOLM‑13 cells are an aggressive and clinically relevant choice for evaluating AML-targeted therapies. These cells grow rapidly in immunocompromised rodents, forming solid tumors ideal for in vivo efficacy studies and modeling drug resistance.

Scientific Background

Established from peripheral blood of a 20‑year‑old AML-M5a patient, MOLM‑13 cells harbor the MLL‑AF9 translocation and trisomy 8, among other chromosomal anomalies. The FLT3-ITD mutation, present in many aggressive AML forms, makes this cell line a standard for assessing FLT3-targeting compounds in preclinical research. MOLM‑13-derived xenografts recapitulate signaling pathways and responses associated with aggressive leukemia, including sensitivity to kinase inhibitors and susceptibility to differentiation therapies.

Study Design by Altogen Labs

Altogen Labs uses 10–12 week old NOD/SCID or athymic BALB/C mice for establishing MOLM‑13 xenografts. Cells are prepared to ≥99% viability and mixed with Matrigel for subcutaneous injection (typically 1×10⁶ cells in 100–200 µL). Tumors form rapidly, reaching a volume of approximately 80–120 mm³ before animals are randomized into treatment arms. Tumor volumes are measured daily with digital calipers while body weights are tracked three times per week. Treatment regimens, dosing routes, and schedules are customized per client specifications. Animals are euthanized according to ethical criteria when tumors reach pre-established endpoints.

Endpoint Measurements and Data Reporting

At study conclusion, Altogen Labs offers a complete report inclusive of tumor growth curves, body weight records, and statistical analyses. Tumors are collected, weighed, imaged, and processed—either frozen or fixed depending on downstream assays. Optional analyses include histopathology, immunohistochemistry, RNA/protein isolation, gene expression profiling, and metabolic or blood chemistry assays. All work occurs in GLP-compliant settings under IACUC supervision, ensuring compliance with regulatory and ethical standards.

Research Applications and Relevance

This model supports evaluation of AML therapies including FLT3 inhibitors, differentiation agents, and immunotherapy candidates. It captures key aspects of aggressive leukemia, such as rapid tumor growth and genetic fidelity to patient-derived disease. MOLM‑13 xenografts are used in studies of tumor growth inhibition (TGI), tumor growth delay (TGD), pharmacokinetics/pharmacodynamics (PK/PD), toxicity screening, and evaluation of resistance mechanisms. Their aggressive growth profile enables fast turnarounds and meaningful treatment comparisons.

Request an Instant Quote: https://altogenlabs.com/request-quote/molm13-xenograft-model-services/

Learn more: MOLM-13 Xenograft Model

MOLT-4 Xenograft Model

Overview of the MOLT‑4 Xenograft Model

The MOLT‑4 xenograft model provides a dynamic and clinically relevant in vivo platform for studying human T‑cell acute lymphoblastic leukemia (T‑ALL). Originating from a 19‑year‑old patient in relapse, the MOLT‑4 cell line reliably engrafts in immunodeficient mice to form palpable tumors that respond to therapeutic interventions. This model is particularly useful for evaluating novel anti‑leukemia agents and understanding T‑ALL treatment resistance and relapse mechanisms.

Scientific Background: MOLT‑4 Cell Line

MOLT‑4 cells are characterized as hypertetraploid human T‑lymphoblasts derived from relapsed T‑ALL and carry a G→A mutation in p53 codon 248. These cells express high levels of T‑cell markers such as CD1, CD2, CD3, CD4, CD5, CD6, and CD7, as well as terminal deoxynucleotidyl transferase (TdT). Their aggressive phenotype and expression profile make them a robust model for studying immunophenotypic responses, signal transduction, and chemotherapy resistance.

Study Protocol by Altogen Labs

Studies are conducted using immunodeficient mouse strains (e.g., NOD/SCID or athymic nude), with 10–12‑week‑old animals used for consistent engraftment. MOLT‑4 cells are cultured in log phase, ensuring ≥98% viability before suspension in Matrigel and subcutaneous implantation (1×10^6 cells in 100 µL). Palpable tumors typically form within 7–10 days. Once tumors reach 120–160 mm³, animals are randomized, and therapeutic compounds are administered on a client-defined schedule. Tumor volumes are measured daily, and body weights are recorded three times weekly. Studies proceed until tumors reach ethical endpoints, at which point animals are humanely euthanized .

Endpoint Analysis and Data Delivery

Altogen Labs provides a detailed final report that includes tumor growth curves, body weight data, statistical analyses, necropsy observations, and high-resolution imaging of tumor samples. Tumors and associated tissues are harvested and processed for downstream analyses including histopathology, immunohistochemistry, RNA/protein extraction, and molecular assays. Samples may be preserved via RNAlater, snap freezing, or formalin fixation based on client requirements. All workflows are conducted in GLP-compliant facilities under IACUC oversight.

Applications and Disease Relevance

The MOLT‑4 xenograft model is widely used to test differentiation therapies, apoptosis inducers, chemotherapeutics targeting T‑ALL, and novel biologics. Its high expression of T‑cell markers enables mechanistic studies of T‑cell receptor signaling and immune escape. The hypertetraploid genotype and relapsed origin support investigations into resistance mechanisms and relapse biology. This model is also an established platform for tumor growth inhibition (TGI) and delay (TGD) analysis, PK/PD assessments, and combinatorial drug testing.

Request an Instant Quote: https://altogenlabs.com/request-quote/

Learn more: MOLT4 Xenograft Model

A20 Xenograft Model

Overview of the A20 Xenograft Model

The A20 xenograft model employs a murine B‑cell lymphoma cell line derived from spontaneous reticulum cell sarcoma in aged BALB/c mice. This syngeneic model retains a fully competent host immune system, enabling in-depth studies on immuno-oncology interventions that engage both tumor and immune components. Tumors form predictably and respond robustly to immunomodulatory agents including checkpoint inhibitors and radiation therapy, making this model a valuable asset for evaluating combination strategies and novel immunotherapies.

Biological Background of A20 Cells

A20 cells originated from a spontaneous B‑cell lymphoma in a BALB/c mouse and are widely used to model non-Hodgkin B‑cell malignancies. These cells express high levels of PD‑L1 and respond effectively to immune-targeting treatments such as anti‑PD‑1, anti‑PD‑L1, and anti‑GITR antibodies. They exhibit moderate doubling times of approximately 4–5 days in vivo, allowing for sufficient therapeutic windows to assess tumor growth inhibition, immune infiltration, and survival outcomes.

Study Design by Altogen Labs

Altogen Labs performs A20 xenograft studies in immunocompetent BALB/c mice. Tumors are established through subcutaneous inoculation of A20 cells, and dosing with test compounds begins once tumors are palpable or reach a defined volume. During the study, tumor dimensions and animal body weights are recorded regularly. Clinical signs and tumor progression are monitored daily. At endpoint, typically determined by tumor size or health criteria, mice undergo necropsy. Tumor tissues are collected for photographic documentation, weighing, and further molecular analysis.

Endpoint Measurements & Data Reporting

Upon study completion, Altogen Labs delivers comprehensive datasets that include tumor growth curves, body weight records, necropsy findings, and image documentation. Optional downstream analyses include histopathology, immunohistochemistry, isolation of RNA/protein, gene expression analysis, and immune profiling. All study activities are carried out in GLP-compliant facilities under strict IACUC oversight, ensuring regulatory compliance and data integrity.

Immuno-Oncology Insights & Application

Because A20 tumors grow in an immunocompetent environment, this model is particularly valuable for evaluating immune checkpoint blockade, costimulatory agonists, CAR-T constructs, cancer vaccines, and combination therapies involving radiation or conventional chemotherapies. It supports assessments of anti-tumor responses, T-cell/macrophage infiltration, and immunomodulatory mechanism interrogation. Dual-mode versions of the model—involving orthotopic or systemic (i.v.) administration and luciferase-labeled cells—enable tracking of metastasis, tumor burden, and long-term treatment outcomes.

Request an Instant Quote: https://altogenlabs.com/request-quote/a20-xenograft-model-services/

Learn more: A20 Xenograft Model

Daudi Xenograft Model

Overview of the Daudi Xenograft Model

The Daudi xenograft model is a well-established in vivo platform for studying Burkitt’s lymphoma and other high-grade B-cell lymphomas. Derived from a human patient with Burkitt’s lymphoma, Daudi cells are lymphoblast-like and represent one of the earliest human B-cell lines successfully adapted to tissue culture. When injected into immunodeficient mice, these cells reliably form subcutaneous tumors, offering a translational model for evaluating novel therapeutic agents, especially monoclonal antibodies, small-molecule inhibitors, and immune-targeted therapies.

Scientific Background: Daudi Cell Line

Daudi cells are Epstein-Barr virus (EBV)-positive and possess several unique biological features that make them ideal for preclinical studies. As mature B lymphocytes, they express surface immunoglobulin, MHC class I and II molecules, and complement receptors. Their consistent expression of CD19 and CD20 surface markers makes them particularly suitable for testing anti-CD20 therapeutics such as rituximab. Additionally, their EBV-positive status allows researchers to investigate virus-host interactions and viral oncogenesis in the context of lymphoma progression. Because Daudi cells are derived from Burkitt’s lymphoma—a highly aggressive B-cell malignancy with characteristic MYC translocations—they also serve as a platform to study deregulated cell proliferation, metabolic reprogramming, and apoptotic pathways.

Xenograft Study Protocol at Altogen Labs

Altogen Labs conducts Daudi xenograft studies in NOD/SCID or athymic nude mice, typically aged 10 to 12 weeks. The Daudi cells are maintained under strict quality control conditions and harvested during logarithmic growth to ensure high viability before implantation. Approximately one million viable cells, suspended in a Matrigel matrix, are injected subcutaneously into the hind flank of each mouse. Tumors usually become palpable within 7 to 10 days, and animals are randomized into treatment groups when tumors reach approximately 100 to 150 cubic millimeters. Tumor measurements are taken with digital calipers several times per week, alongside regular monitoring of body weight and overall health. Study duration is customized according to the therapeutic regimen and experimental goals. When ethical or volume-based endpoints are reached, animals are humanely euthanized in accordance with IACUC-approved protocols.

Endpoint Analysis and Reporting

Upon study completion, Altogen Labs provides a comprehensive report that includes tumor growth kinetics, body weight data, high-resolution imaging, necropsy observations, and tumor measurements. Tissue samples are collected, weighed, and preserved according to the client’s intended downstream applications. Available post-study services include histological evaluation, immunohistochemistry, flow cytometry, qRT-PCR, RNA/protein extraction, and ELISA. The study is conducted in GLP-compliant, pathogen-free facilities with full adherence to regulatory standards and ethical oversight.

Research Applications and Relevance

The Daudi xenograft model is widely used to evaluate drug candidates targeting surface antigens, intracellular kinases, and immune checkpoints involved in B-cell malignancies. Its compatibility with monoclonal antibody-based therapeutics makes it ideal for testing anti-CD20 and anti-CD19 agents. Researchers can also use this model to study lymphoma microenvironment dynamics, tumor immune evasion mechanisms, and resistance to frontline therapies. Due to its EBV positivity, the model can support research into virus-associated oncogenesis and latent viral protein expression in a tumor setting.

Request an Instant Quote: https://altogenlabs.com/request-quote/

Learn more: Daudi Xenograft Model

Raji Xenograft Model

Overview of the Raji Xenograft Model

The Raji xenograft model provides an aggressive, immunodeficient in vivo system for studying human Burkitt’s lymphoma and related B-cell malignancies. Derived from the peripheral blood of an 11-year-old patient with Burkitt’s lymphoma, Raji cells retain characteristics of mature B lymphocytes and have been extensively used in oncology research. When implanted into suitable mouse models, Raji cells generate solid tumors that serve as a robust platform for preclinical drug testing, including antibody-based therapies and targeted small molecules.

Scientific Background: Raji Cell Line

Raji cells are Epstein-Barr virus (EBV)-positive and carry hallmark mutations found in high-grade B-cell lymphomas, such as c-MYC translocations that drive unchecked proliferation. These cells express key B-cell surface antigens including CD19, CD20, CD22, and HLA-DR, making them a valuable model for therapies targeting B-cell surface markers. Raji cells are also used in immunotherapy studies due to their expression of MHC class I and II molecules, as well as their susceptibility to immune-mediated cytotoxicity. Their EBV positivity allows researchers to explore interactions between viral oncogenes and tumor progression mechanisms in vivo.

Xenograft Study Design by Altogen Labs

Altogen Labs establishes Raji xenografts using immunodeficient mice, typically NOD/SCID or athymic nude strains, aged between 10 and 12 weeks. Raji cells are harvested during log-phase growth at ≥98% viability and suspended in a matrix such as Matrigel before subcutaneous injection into the flank of each mouse. Tumors typically begin to form within one week and are closely monitored until reaching a target size for randomization. Tumor volume and body weight are recorded at least three times weekly. Treatment regimens—including compound type, route of administration, and schedule—are fully customized to meet specific experimental objectives. Mice are ethically euthanized once tumors reach study endpoints or if predefined health criteria are met.

Endpoint Analysis and Study Output

Altogen Labs delivers a full data package that includes tumor growth curves, body weight tracking, digital imaging, necropsy reports, and tumor tissue measurements. Clients can request a variety of follow-up analyses such as histology, immunohistochemistry, flow cytometry, protein or RNA extraction, and gene expression profiling. Optional immune cell analysis is available when using humanized or co-engrafted models. All work is conducted in GLP-compliant facilities with IACUC-approved protocols, ensuring consistent, high-quality results suitable for regulatory documentation or publication.

Research Applications and Utility

The Raji xenograft model supports evaluation of a wide spectrum of anti-cancer agents, particularly monoclonal antibodies such as anti-CD20 (e.g., rituximab) and anti-CD19 compounds. Its aggressive growth rate and stable phenotype make it ideal for screening novel therapies and combination regimens. Because the Raji cell line is EBV-positive, the model also enables investigation into virus-associated lymphomagenesis and the effects of therapies targeting latent viral proteins. It is frequently used in studies focused on B-cell receptor signaling, immune escape, apoptosis, and chemotherapy resistance mechanisms.

Request an Instant Quote: https://altogenlabs.com/request-quote/raji-xenograft-model-services/

Learn more: Raji Xenograft Model

EL4 Xenograft Model

Overview of the EL4 Xenograft Model

The EL4 xenograft model is a widely used syngeneic system for studying murine T‑cell lymphoma in immunocompetent mice. Derived from a chemically induced lymphoma in C57BL/6 mice, EL4 cells enable researchers to evaluate anti-tumor therapies within a fully functional immune system. This model is particularly valuable for preclinical assessment of immunotherapies, checkpoint inhibitors, cytokine treatments, radiation, and combination regimens, providing a translationally relevant platform for studying T‑cell mediated oncogenesis and tumor-immune interactions.

Scientific Background: EL4 Cell Line

EL4 cells are a murine lymphoma cell line that originated from a C57BL/6 mouse and represent an undifferentiated T‑lymphoblastic phenotype. These cells express T‑cell surface markers such as CD3 and CD4 and exhibit high mitotic activity and tumorigenic potential. Because they are syngeneic to the C57BL/6 mouse strain, EL4 cells allow tumor development in a host with an intact immune system. This feature is essential for modeling the dynamics of immune surveillance, T-cell activation, and resistance to immunotherapy. EL4 cells have also been engineered in various experimental systems to express tumor antigens or human immune markers, enhancing their utility in targeted therapy research.

Xenograft Study Protocol at Altogen Labs

Altogen Labs conducts EL4 xenograft studies using young adult C57BL/6 mice, typically 6 to 10 weeks old. EL4 cells are prepared in log-phase growth, achieving high viability before injection. Each mouse receives a subcutaneous flank injection of one million EL4 cells suspended in a Matrigel or PBS matrix. Tumor growth is closely monitored, and once tumors reach a volume of approximately 100 mm³, animals are randomized into treatment cohorts. Test compounds are administered according to client specifications, with common routes including intravenous, intraperitoneal, or subcutaneous delivery. Tumor volumes and animal body weights are recorded multiple times per week, and any signs of distress are documented in compliance with animal welfare protocols. At study endpoint—defined either by tumor size, health status, or duration—mice are humanely euthanized for tissue collection and analysis.